Name: Velaglucerase alfa

---

Type: biotech

---

Groups: Array

---

Indication: Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.

---

Accession Number: DB06720 ( DB06720)

---

Description: Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.

---

Structure:

---

Prescription Products:

Name	Dosage	Strength	Route	Marketing Start	Marketing End	Country
Vpriv	injection, powder, lyophilized, for solution	2.5 mg/mL	intravenous	26-02-2010		US
Vpriv	powder for solution	400 unit	intravenous	22-11-2010		Canada

---

Generic Prescription Products: Not Available

---

Over the Counter Products: Not Available

---

International Brands

• No Brands

---

Brand Names

• No Brands

---

Brand Mixtures

Brand Name	Ingredients
Vpriv	Velaglucerase alfa
Vpriv	Velaglucerase alfa

Brand Name	Ingredients
Vpriv	Velaglucerase alfa
Vpriv	Velaglucerase alfa

---

Categories

• Enzymes

Indication: Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.

---

Pharmacodynamics: Not Available

---

Mechanism of action: Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.

---

Absorption: Not Available

---

Volume of distribution:

The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight).

---

Protein binding: Not Available

---

Metabolism: Not Available

---

Route of elimination: Not Available

---

Half life: 11-12 minutes.

---

Clearance: Not Available

---

Toxicity: Not Available

---

Affected organisms

• Not Available

---

SNP Mediated Adverse Drug Reactions

• Not Available

Manufacturers:

• Not Available

---

Packagers:

• Not Available

---

Dosage forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	intravenous	2.5 mg/mL
Powder for solution	intravenous	400 unit

Form	Route	Strength
Injection, powder, lyophilized, for solution	intravenous	2.5 mg/mL
Powder for solution	intravenous	400 unit

---

Prices

Unit description	Cost	Unit

Unit description	Cost	Unit

---

Patents

Country	Patent Number	Approved	Expires (estimated)
7138262	United States	2006-11-21	2020-08-18

Drug Interactions

Drug	Interaction

Drug	Interaction

---

Food Interactions:

• Not Available

Kingdom: Organic Compounds

---

Super Class: Not Available

---

Class: Not Available

---

Sub Class: Not Available

---

Direct Parent: Not Available

---

Alternative Parents:

• Not Available

---

substituent:

• Not Available

Synthesis Reference: Not Available

---

General Reference: # Pastores GM: Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr Opin Investig Drugs. 2010 Apr;11(4):472-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20336596 # Vairo F, Netto C, Dorneles A, Mittelstadt S, Wilke M, Doneda D, Michelin K, Ribeiro CB, Quevedo A, Vieira T, Nalin T, Lueska S, Schwartz IV: Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD Rep. 2013 Feb 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23430813

---

External Links:

Resource	Link
RxList	http://www.rxlist.com/vpriv-drug.htm
PDRhealth	http://www.pdrhealth.com/info/v1us/vpriv
Drugs.com	http://www.drugs.com/vpriv.html3

Resource	Link
RxList	http://www.rxlist.com/vpriv-drug.htm
PDRhealth	http://www.pdrhealth.com/info/v1us/vpriv
Drugs.com	http://www.drugs.com/vpriv.html3

---

ATC Codes:

• Array

---

AHFS Codes:

• Not Available

---

MSDS: Download